Gravity Analytica

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

CPIX 10.31.2024

SERA-AI Powered Highlights

Drug:CPIX-001 Acetadote® (acetylcysteine)

Drug:CPIX-002 Caldolor® (ibuprofen)

Drug:CPIX-003 Kristalose® (lactulose)

Drug:CPIX-004 Sancuso® (granisetron)

Drug:CPIX-005 Vaprisol® (conivaptan)

Drug:CPIX-006 Vibativ® (telavancin)

Diseases:Acetaminophen poisoning

Diseases:Pain and fever

Diseases:Constipation

Diseases:Chemotherapy-induced nausea and vomiting

Diseases:Hyponatremia

Diseases:Bacterial infections

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Cumberland Pharmaceuticals Conference Call

Full Press Release SEC Filings Our CPIX Tweets

About Gravity Analytica

Recent Filings

NASHVILLE, Tenn.,Oct. 31, 2024/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes onThursday, Nov. 7, 2024.

A conference call will be held onNov. 7at4:30 p.m. Eastern Timeto discuss the results. To participate in the call, please register athttps://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed viaCumberland'swebsite or by visitinghttps://edge.media-server.com/mmc/p/cm7m7ea3.

Cumberland Pharmaceuticalsis a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.

The company's portfolio of FDA-approved brands includes:

Acetadote^®(acetylcysteine) injection, for the treatment of acetaminophen poisoning;
Caldolor^®(ibuprofen) injection, for the treatment of pain and fever;
Kristalose^®(lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
Sancuso^®(granisetron)transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
Vaprisol^®(conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
Vibativ^®(telavancin) injection, for the treatment of certain serious bacterial infections includinghospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.

For more information onCumberland'sapproved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website atwww.cumberlandpharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2024-financial-results-302293344.html

SOURCECumberland Pharmaceuticals Inc.

Investor Contact: Shayla Simpson, Cumberland Pharmaceuticals, (615) 255-0068; Media Contact: Molly Aggas, Dalton Agency, (704) 641-6641

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com